Advanced Lab Reagents Market Report 2026

The advanced lab reagents market size has grown rapidly in recent years. It will grow from $1.67 billion in 2025 to $1.87 billion in 2026 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to growing pharmaceutical and biotechnology R&D activities, increasing investment in academic and research laboratories, rising prevalence of chronic and infectious diseases, expanding adoption of molecular diagnostics technologies, increasing demand for high sensitivity analytical testing.

The advanced lab reagents market size is expected to see rapid growth in the next few years. It will grow to $2.92 billion by 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to growing expansion of precision medicine applications, rising adoption of automated laboratory workflows, increasing demand for cell and gene therapy research, expanding use of biomarker based diagnostics, growing investments in advanced biologics and biosimilar development. Major trends in the forecast period include increasing adoption of high purity and contamination free reagents, growing demand for reproducible and standardized laboratory workflows, rising use of multiplex and high throughput assay reagents, increasing focus on customized and application specific reagent formulations, growing utilization of advanced reagents in clinical diagnostics and translational research.

The rising prevalence of chronic diseases is expected to propel the growth of the advanced lab reagents market going forward. Chronic diseases are long-term medical conditions such as arthritis, cancer, and cardiovascular disorders that require continuous diagnosis, monitoring, and treatment over extended periods. The increasing prevalence of chronic diseases is primarily contributing to aging populations, which significantly raises susceptibility to long-term health conditions. Advanced lab reagents support the growing burden of chronic diseases by enabling precise biomarker detection, disease monitoring, and high-throughput diagnostic testing, thereby facilitating early diagnosis and effective long-term disease management. For instance, in February 2024, according to the Centers for Disease Control and Prevention, the proportion of individuals living with multiple chronic conditions in the US increased from 42% in 2024 to 51% in 2025, reflecting a notable upward trend in disease burden across the population. Therefore, the rising prevalence of chronic diseases is driving the growth of the lung cancer screening market.

Leading companies operating in the advanced lab reagents market are focusing on technological advancement in lab automation, such as automation-compatible internalization assay reagents, to improve workflow efficiency, scalability, and data accuracy in drug discovery processes. Automation-compatible internalization assay reagents refer to specialized biochemical reagents designed to work seamlessly with automated, plate-based laboratory systems, enabling high-throughput analysis of cellular processes such as receptor internalization with minimal manual intervention. For example, in June 2025, Revvity, Inc., a US-based life sciences company, launched pHSense reagents, a novel reagent technology designed for high-throughput internalization studies in GPCR and antibody-drug conjugate (ADC) research. The product features a pH-sensitive dye combined with time-resolved fluorescence (TRF) for enhanced detection sensitivity, provides robust kinetic measurement of internalization even at low receptor expression levels, and is fully compatible with standard plate readers and automated workflows, enabling easy integration into existing laboratory systems.

In July 2024, Thermo Fisher Scientific, a US-based provider of analytical instruments, life sciences solutions, specialty diagnostics, and laboratory services, acquired Olink Holding AB for approximately $3.1 billion. With this acquisition, Thermo Fisher seeks to strengthen its position in the rapidly growing proteomics sector by combining Olink’s advanced protein analysis technologies with its existing mass spectrometry and life sciences portfolio to accelerate scientific research and precision medicine innovation. Olink Holding AB is a Sweden-based company offering next-generation proteomics solutions, including biomarker discovery platforms, assay kits, and reagent-based technologies for high-throughput protein analysis.

Major companies operating in the advanced lab reagents market are Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Lonza Group AG, Agilent Technologies Inc., Sartorius AG, Waters Corporation, Bio-Rad Laboratories Inc., QIAGEN N. V., Bio-Techne Corporation, GenScript Biotech Corporation, Promega Corporation, New England Biolabs Inc., Cell Signaling Technology Inc., OriGene Technologies Inc., Elabscience Biotechnology Inc., RayBiotech Inc., Proteintech Group Inc., Santa Cruz Biotechnology Inc., Rockland Immunochemicals Inc., Creative Biolabs Inc., Bioss Antibodies Inc., Creative Diagnostics LLC, Boster Biological Technology Co. Ltd., Abbexa Ltd.

North America was the largest region in the advanced lab reagents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced lab reagents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the advanced lab reagents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The advanced lab reagents market consists of sales of molecular biology reagents, cell culture reagents, immunoassay reagents, chromatography reagents, analytical standards, specialty chemicals, and diagnostic reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.